X4 Pharmaceuticals is undergoing intensive strategic restructuring to focus exclusively on advancing mavorixafor for Chronic Neutropenia (CN), de-prioritizing the WHIM indication. The company effected significant workforce reductions totaling approximately 80% across Q1 and Q3 2025, incurring $7.2 million in severance costs to align resources for the global Phase 3 4WARD trial (enrollment targeted for Q3 2026).
Financially, the nine months ended September 30, 2025, resulted in a Net Loss of \((55.3) million, contrasting sharply with the prior year's net income (which included a \)105M asset sal
...